Michael S. Abrams its chief financial officer.
In alignment with the company’s succession plan, Abrams joins Arch’s financial team in the role previously held by Richard Davis. Davis will remain with the company during a transition period, which will end on June 30, after which he will support the company in a consulting role through Dec. 31.
Abrams has more than 25 years of experience as a chief financial officer to numerous public and private companies; principal investor; investment banker; merchant banker; strategic and financial adviser; and board member. His capabilities span a broad range of activities with a particular expertise in the areas of operational management, complex financial engineering, financial advisory and capital markets strategy primarily for companies in the technology and healthcare sectors.
Operator
Good afternoon, ladies and gentlemen, and welcome to the Spectrum Pharmaceuticals First Quarter 2021 Earnings Conference Call. [Operator Instructions]
I would now like to turn the conference over to your host, Mr. Kurt Gustafson, Chief Financial Officer.
Kurt A. Gustafson
Executive Vice President and Chief Financial Officer
Thank you, operator, and good afternoon to everyone. Thank you for joining us today for Spectrum Pharmaceuticals first quarter 2021 financial results conference call. Our first quarter financial results press release was sent out earlier this afternoon, and is available on our website at www.sppirx.com.
Joining me on the call today from Spectrum Pharmaceuticals will be Joe Turgeon, President and CEO, and Dr. Francois Lebel, Chief Medical Officer.
Cancer is a leading cause of death worldwide and is projected to rise with an estimated 11.5 million deaths in 2030. The most common cancer is lung cancer, accounting about 1.59 million deaths, other types of cancer include liver cancer, breast cancer, stomach cancer, liver cancer, etc. Cancer can be treated by sur.
Spectrum Pharma: Q1 Earnings Snapshot
by The Associated Press
Last Updated May 13, 2021 at 4:14 pm EDT
HENDERSON, Nev. (AP) Spectrum Pharmaceuticals Inc. (SPPI) on Thursday reported a loss of $35.7 million in its first quarter.
On a per-share basis, the Henderson, Nevada-based company said it had a loss of 25 cents.
The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 33 cents per share.
In the final minutes of trading on Thursday, the company’s shares hit $3.07. A year ago, they were trading at $3.11.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on SPPI at https://www.zacks.com/ap/SPPI